Dublin-based personal healthcare firm Integumen, listed on London's AIM, is planning to raise £7.5m (€8.7m) as it buys Galway-based firm Cellulac, which has developed products to make biodegradable plastic used in the cosmetics, nutritional food and healthcare sectors. Dublin-based personal healthcare firm Integumen, listed on London's AIM, is planning to raise £7.5m (€8.7m) as it buys Galway-based firm Cellulac, which has developed products to make biodegradable plastic used in the cosmetics, nutritional food and healthcare sectors. Cellulac is owned by investors including Gerard Brandon, once the chief executive of Irish wound-care firm Alltracel. Upon completion of the deal, which will constitute a reverse takeover, Mr Brandon will become chief executive of Integumen, whose name will be changed to Cellulac. Mr Richardson is also chief executive of drug-development firm Venn Life Sciences, which owns about a quarter of Integumen.

Source: Irish Independent April 17, 2018 01:30 UTC